Last November, Pharmaceutical Online had the privilege of visiting GSK’s U.S. global R&D hub in Upper Providence, Pa. The 1.4-million sq. ft. facility will soon house the company’s consolidated U.S. R&D activities across the areas of HIV and infectious disease, oncology, immune-inflammation, metabolic pathways and cardiovascular, and dermatology. By 2018, it will be home to more than 3,200 employees, who will collaborate on target identification, safety studies, active pharmaceutical ingredient (API) manufacture, and many other R&D-related activities.
{iframe}https://www.pharmaceuticalonline.com/doc/how-gsk-launched-a-continuous-manufacturing-pilot-plant-and-what-it-learned-0001?vm_tId=2013612&user=4DCE7014-E294-4E2C-8981-D15F691A9B9A&utm_source=et_6214180&utm_medium=email&utm_campaign=PHARM_08-01-2017&utm_term=4DCE7014-E294-4E2C-8981-D15F691A9B9A&utm_content=How+GSK+Launched+A+Continuous+Manufacturing+Pilot+Plant%253a+And+What+It+Learned{/iframe}